OUR APPROACH
EVOQ Therapeutics is pioneering the development of a proprietary technology that represents a genuine breakthrough for autoimmune disease therapy.
Autoimmune Disease Vaccines
EVOQ's technology has demonstrated breakthrough efficacy in the gold-standard preclinical models of Multiple Sclerosis (MS) and Type-1 Diabetes (T1D). Success with these preclinical models is considered proof of concept for the potential utility of a therapy in a wide range of autoimmune diseases.
With prevalence on the rise, autoimmune diseases have a devastating impact on the lives of 23.5 million Americans, and millions more of children and adults around the world.
Examples include:
-
Type 1 Diabetes
-
Celiac disease
-
Multiple sclerosis
-
Neuromyelitis optica
-
Rheumatoid arthritis
-
Myasthenia gravis
-
Pemphigus
-
Graves' disease

EVOQ's technology utilizes a proprietary synthetic HDL NanoDisc that has been optimized to deliver antigens to dendritic cells residing in lymph nodes.